Mabquest Therapeutics Trademark Application Published for Opposition

ChangeBridge: Trademarks - Pharmaceuticals (Class 005)

Published July 29th, 2025

Detected March 27th, 2026

Summary

The USPTO has published the trademark application for 'Mabquest Therapeutics' for opposition. The application covers pharmaceutical products for treating cancer, autoimmune diseases, and inflammatory disorders, among other related medical preparations and diagnostic agents. The publication date is March 26, 2026, with a filing date of July 29, 2025.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'Mabquest Therapeutics' (Application No. TM79435367) for opposition. This publication signifies that the application has passed initial examination and is now open to challenges from third parties who may believe the mark infringes on their existing rights. The application seeks to register trademarks for a broad range of pharmaceutical products and services, including those for the treatment of cancer, autoimmune diseases, inflammatory disorders, and conditions within oncology and immunology.

While this is a trademark publication and not a direct regulatory rule, it is a critical step in the process of securing exclusive rights to use the mark in commerce. Companies operating in the pharmaceutical and biotechnology sectors should monitor this publication, especially if they have existing marks or products in similar therapeutic areas, to assess potential conflicts. The opposition period, which follows this publication, allows interested parties to file a notice of opposition to prevent the registration of the mark. The filing date for this application was July 29, 2025, and it was published for opposition on March 26, 2026.

What to do next

Monitor trademark opposition period for 'Mabquest Therapeutics' application TM79435367 if potential conflicts exist.

Source document (simplified)

← USPTO Trademark Applications

MABQUEST THERAPEUTICS

Published for Opposition TM79435367 Kind: published Mar 26, 2026

Abstract

Pharmaceutical products for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; medicinal preparations for disease treatment, namely, for preventing or treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; preparations for medical treatments, in particular preparations based on polypeptides and proteins for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; protein complexes for diagnosing cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; synthetic peptides for pharmaceutical use, namely, for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; diagnostic agents, preparations and substances for medical purposes; diagnostic substances for medical use; medicinal preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; pharmaceutical preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; agents and medicines for therapeutic use, namely, for the treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; cells for medical use; chemical, biochemical and biological preparations being biological, biochemical, and immunological pharmaceutical preparations for medical use; Chemical, biochemical, biological and biotechnological preparations for use in industry and science other than for medical or veterinary use; chemical, biological and biotechnological preparations, in particular polypeptides and proteins for development or manufacture of reagents for use in industry and science; biological preparations, in particular polypeptides or proteins for use in laboratories and for non-medical diagnosis and analysis in industry and science; chemical and biochemical substances being additives for use in the manufacture of pharmaceuticals; chemical and biochemical substances for use in the manufacture of pharmaceuticals for treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; stem cells for research purposes; stem cells for scientific use; cultures of microorganisms other than for medical and veterinary use; cell culture media for scientific and research purposes; Analysis and research in laboratories being research laboratory analysis services in the field of chemistry, biochemistry, and molecular biology; scientific research and analysis in the field of chemistry, biochemistry, molecular biology, and immunology; cell culture for scientific research purposes, for others; design and development of medical technologies; research and development in the field of biotechnology; research and development in the field of microorganisms and cells; research and development in the field of diagnostic preparations; pharmaceutical research and development; biochemical research and development; scientific and technological research, particularly in the biochemical, diagnostic or pharmaceutical fields; research and development for the pharmaceutical industry; research and development services in the field of proteins, microorganisms and cells; research and development services in the field of immunology; services of a chemical, biochemical and biological research laboratory; research services, namely, analyses in the field of molecular biology